![Gabriel R. Cipau](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gabriel R.
Cipau is an Executive Chairman of Phase Bioscience, Inc. He is a Director of ENS, Inc. and Bob Barker Co. and a Partner at Key Healthcare Partners.
Dr. Cipau was President and Chief Executive Officer of Nippon Wellcome Kk, Copley Pharmaceuticals, Catalytica Pharmaceuticals, and Biolex, Inc. He was Chief Executive Officer of Phase Bioscience until March, 2007.
Dr. Cipau holds an MBA and PhD.
| Unternehmen | Position | Beginn |
|---|---|---|
ENS, Inc.
 ENS, Inc. Medical/Nursing ServicesHealth Services Home care nursing concern | Direktor/Vorstandsmitglied | - |
| Unternehmen | Position | Ende |
|---|---|---|
DSM Pharmaceuticals, Inc.
 DSM Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical & biotechnology contract manufacturing services | Präsident | - |
Biolex Therapeutics, Inc.
 Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Develops and produces drugs | Präsident | - |
| PHASEBIO PHARMACEUTICALS, INC. | Vorsitzender | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
DSM Pharmaceuticals, Inc.
DSM Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical & biotechnology contract manufacturing services | Health Technology |
Biolex Therapeutics, Inc.
Biolex Therapeutics, Inc. Medical DistributorsDistribution Services Develops and produces drugs | Distribution Services |
PhaseBio Pharmaceuticals, Inc.
 PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
ENS, Inc.
ENS, Inc. Medical/Nursing ServicesHealth Services Home care nursing concern | Health Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
